Effects of resistance training on sleep quality and disorders among individuals diagnosed with cancer: A systematic review and meta ‐analysis of randomized controlled trials
ConclusionRT interventions of 60 minutes per session, performed 2–3 times a week for 12 weeks, with exercise intensity ranging from 60% to 80% of one-repetition maximum can be administered to cancer survivors, aiming to improve sleep outcomes. (Source: Cancer Medicine)
Source: Cancer Medicine - April 23, 2024 Category: Cancer & Oncology Authors: Dora Maric,
Salvatore Ficarra,
Luca Di Bartolo,
Carlo Rossi,
Zoi Asimakopoulou,
Apostolos Vantarakis,
Ana Carbonell‐Baeza,
David Jiménez‐Pavón,
Beatriz Gomes,
Paula Tavares,
Rebecca Baxter,
Susanna Pusa,
Petra Thaller,
Sofia Papakonst Tags: REVIEW Source Type: research
Adaptive radiotherapy for head and neck cancer: Pitfalls and possibilities from the radiation oncologist's point of view
ConclusionAlthough based on mainly non-randomized and retrospective trials, there is accumulating evidence that ART has the potential to reduce toxicity and improve quality of life and tumor control in HNC patients treated with RT. However, several questions remain regarding accurate patient selection, the ideal frequency and timing of replanning, and the appropriate way for image registration and dose calculation. Well-designed randomized prospective trials, with a predetermined protocol for both image registration and dose summation, are urgently needed to further investigate the dosimetric and clinical benefits of ART. ...
Source: Cancer Medicine - April 23, 2024 Category: Cancer & Oncology Authors: Sandra Nuyts,
Heleen Bollen,
Avrahram Eisbruch,
Primoz Strojan,
William M. Mendenhall,
Sweet Ping Ng,
Alfio Ferlito Tags: REVIEW Source Type: research
Incidence and prevalence of musculoskeletal health conditions in survivors of childhood and adolescent cancers: A report from the Swiss childhood cancer survivor study
ConclusionMSHCs are prevalent in survivors, the risk is increasing in younger survivor cohorts, and MSHCs usually occur in multimorbid survivors. Strengthening of rehabilitation services and appropriate referrals are needed to mitigate the effects of the cancer and cancer treatment. (Source: Cancer Medicine)
Source: Cancer Medicine - April 23, 2024 Category: Cancer & Oncology Authors: Salome Christen,
Katharina Roser,
Luzius Mader,
Maria Otth,
Katrin Scheinemann,
Grit Sommer,
Claudia Kuehni,
Gisela Michel Tags: RESEARCH ARTICLE Source Type: research
Disparities in incidence and survival for patients with Ewing sarcoma in Florida
ConclusionsFlorida Hispanic males have a higher-than-expected incidence of osseous ES compared to the US. Hispanics of both sexes show remarkably worse survival for nonmetastatic disease compared to NHW. This disparity is likely multifactorial and requires further in-depth studies. (Source: Cancer Medicine)
Source: Cancer Medicine - April 23, 2024 Category: Cancer & Oncology Authors: Aditi Dhir,
Rachna Rahul,
Qinran Liu,
Dan Pham,
Rachel Kronenfeld,
Tulay Koru ‐Sengul,
Paulo S. Pinheiro Tags: RESEARCH ARTICLE Source Type: research
Metabolite signature of human malignant thyroid tissue: A systematic review and meta ‐analysis
ConclusionIt appears that the field of TC metabolomics will experience notable advancement, leading to the discovery of trustworthy diagnostic and prognostic biomarkers. (Source: Cancer Medicine)
Source: Cancer Medicine - April 22, 2024 Category: Cancer & Oncology Authors: S. Adeleh Razavi,
Babak Khorsand,
Pouya Salehipour,
Mehdi Hedayati Tags: REVIEW Source Type: research
Review of patient ‐reported outcomes (PROs) and non‐PROs in randomized controlled trials addressing head/neck cancers
ConclusionsThere has been a growth in the types of PROs in more recent years, and they were more frequently reported in RCTs. However, head/neck cancer trials with a combination of PROs and non-PROs were the most prevalent. (Source: Cancer Medicine)
Source: Cancer Medicine - April 22, 2024 Category: Cancer & Oncology Authors: Michelle Gode,
Clovis Mariano Faggion Jr Tags: REVIEW Source Type: research
Trends in colorectal cancer screening compliance and incidence among 60 ‐ to 74‐year‐olds in China
ConclusionThis study reported several risk factors associated with the screening behaviors for CRC. Patterns and trends in CRC, AA, ACN, and CN compliance and detection rates correlate with risk factors. (Source: Cancer Medicine)
Source: Cancer Medicine - April 18, 2024 Category: Cancer & Oncology Authors: Mingqing Zhang,
Yongdan Zhang,
Lu Guo,
Lizhong Zhao,
Haoren Jing,
Xiao Yang,
Wen Zhang,
Yong Zhang,
Zhenguo Nie,
Siwei Zhu,
Shiwu Zhang,
Xipeng Zhang Tags: RESEARCH ARTICLE Source Type: research
Long noncoding RNA small nucleolar RNA host genes as prognostic molecular biomarkers in hepatocellular carcinoma: A meta ‐analysis
ConclusionsIn conclusion, upregulation of SNHGs expression correlates with shorter OS, RFS, DFS, tumor size and numbers, histologic grade, lymphatic metastasis, vein invasion, tumor stage, PVTT, and AFP level, suggesting that SNHGs may serve as prognostic biomarkers in HCC. (Source: Cancer Medicine)
Source: Cancer Medicine - April 18, 2024 Category: Cancer & Oncology Authors: Meng Huang,
Zhiwen Zhao,
Lihua Yang Tags: REVIEW Source Type: research
Current treatment and novel insights regarding ROS1 ‐targeted therapy in malignant tumors
ConclusionsFurther research on next-generation TKIs regarding the localization of ROS1 and its fusion partners, binding sites for targeted drugs, and coadministration with other drugs is required. The correlation between TKIs and chemotherapy or immunotherapy in clinical practice requires further study. (Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Shizhe Li,
He Zhang,
Ting Chen,
Xiaowen Zhang,
Guanning Shang Tags: REVIEW Source Type: research
Understanding the financial cost of cancer clinical trial participation
ConclusionCancer clinical trial-related financial hardship, most often stemming from travel expenses, affected almost half of trial-enrolled patients. Interventions are needed to reduce adverse financial participation effects and potentially improve cancer clinical trial participation. (Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Courtney P. Williams,
Luqin Deng,
Nicole E. Caston,
Kathleen Gallagher,
Rebekah Angove,
Maria Pisu,
Andres Azuero,
Rebecca Arend,
Gabrielle B. Rocque Tags: RESEARCH ARTICLE Source Type: research
Impact of immune ‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
ConclusionsThe results of this study show that immune-related adverse events are associated with improved survival outcomes in patients with extensive-stage small cell lung cancer. (Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Tadashi Nishimura,
Hajime Fujimoto,
Takumi Fujiwara,
Kentaro Ito,
Atsushi Fujiwara,
Hisamichi Yuda,
Hidetoshi Itani,
Masahiro Naito,
Shuji Kodama,
Kazuki Furuhashi,
Akihiko Yagi,
Haruko Saiki,
Taro Yasuma,
Tomohito Okano,
Atsushi Tomaru,
Mo Tags: RESEARCH ARTICLE Source Type: research
Off ‐label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center
ConclusionsAt our institution, ICI was most commonly prescribed in the relapsed/refractory setting to patients with metastatic disease. The treatment was generally well-tolerated in the pediatric population. The overall response rate was low, and the majority of patients eventually experienced disease progression. A few patients, however, had durable treatment responses. Further studies are needed to identify which pediatric patients are most likely to benefit from ICI. (Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Ajami Gikandi,
Susan N. Chi,
Kee Kiat Yeo,
Allison F. O'Neill,
David S. Shulman,
Steven G. DuBois,
Natalie B. Collins Tags: RESEARCH ARTICLE Source Type: research
Outcomes of the transformation of follicular lymphoma to diffuse large B ‐cell lymphoma in the rituximab era: A population‐based study
ConclusionThe outcome of t-DLBCL in the rituximab era was better than historical series before the rituximab era. Due to the good prognosis, we did not recommend autologous stem cell transplantation for t-DLBCL receiving watch-and-wait or radiation as initial therapy before HT. (Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Wenshuai Zheng,
Mingjuan Liu,
Lixun Guan,
Shenyu Wang Tags: RESEARCH ARTICLE Source Type: research
Identifying predictors of COVID ‐related delays in cancer‐specific medical care
ConclusionThese findings may inform cancer care delivery during periods of instability when treatment may be disrupted by informing clinicians about concerns that patients have during the treatment process. Future research should assess whether delays in cancer care impact long-term cancer outcomes and whether delays exacerbate existing disparities in cancer outcomes. (Source: Cancer Medicine)
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Breanna B. Greteman,
Natalie J. Del Vecchio,
Crystal J. Garcia‐Auguste,
Amanda R. Kahl,
Brian M. Gryzlak,
Elizabeth A. Chrischilles,
Mary E. Charlton,
Sarah H. Nash Tags: RESEARCH ARTICLE Source Type: research
Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial
This study was conducted to compare the clinical outcome of surufatinib combined with TAE versus surufatinib monotherapy in liver metastatic NETs.MethodsThis is a prospective, multicenter, open-label, and randomized controlled trial. Patients diagnosed with liver metastatic NETs will be enrolled. Participants are randomly assigned in a 1:1 ratio to either the experimental group or the control group. Patients will be treated with surufatinib plus TAE in the experimental group, while patients in the control group will receive surufatinib monotherapy. The primary endpoint is progression-free survival (PFS) assessed by a blind...
Source: Cancer Medicine - April 17, 2024 Category: Cancer & Oncology Authors: Ruizhen Li,
Xiaofen Li,
Xin You,
Minggang Su,
Yuzhi Liu,
Nengwen Ke,
Dan Cao Tags: RESEARCH ARTICLE Source Type: research
